Akbar K Waljee1,2, Kay Sauder2, Anand Patel3, Sandeep Segar3, Boang Liu4, Yiwei Zhang4, Ji Zhu4, Ryan W Stidham2, Ulysses Balis5, Peter D R Higgins2. 1. Department of Veterans Affairs Center for Clinical Management Research, Ann Arbor, MI, USA. 2. Division of Gastroenterology, University of Michigan, Ann Arbor, MI, USA. 3. Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. 4. Department of Statistics, University of Michigan, Ann Arbor, MI, USA. 5. Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
Abstract
BACKGROUND AND AIMS: Big data analytics leverage patterns in data to harvest valuable information, but are rarely implemented in clinical care. Optimising thiopurine therapy for inflammatory bowel disease [IBD] has proved difficult. Current methods using 6-thioguanine nucleotide [6-TGN] metabolites have failed in randomized controlled trials [RCTs], and have not been used to predict objective remission [OR]. Our aims were to: 1) develop machine learning algorithms [MLA] using laboratory values and age to identify patients in objective remission on thiopurines; and 2) determine whether achieving algorithm-predicted objective remission resulted in fewer clinical events per year. METHODS: Objective remission was defined as the absence of objective evidence of intestinal inflammation. MLAs were developed to predict three outcomes: objective remission, non-adherence, and preferential shunting to 6-methylmercaptopurine [6-MMP]. The performance of the algorithms was evaluated using the area under the receiver operating characteristic curve [AuROC]. Clinical event rates of new steroid prescriptions, hospitalisations, and abdominal surgeries were measured. RESULTS: Retrospective review was performed on medical records of 1080 IBD patients on thiopurines. The AuROC for algorithm-predicted remission in the validation set was 0.79 vs 0.49 for 6-TGN. The mean number of clinical events per year in patients with sustained algorithm-predicted remission [APR] was 1.08 vs 3.95 in those that did not have sustained APR [p < 1 x 10-5]. Reductions in the individual endpoints of steroid prescriptions/year [-1.63, p < 1 x 10-5], hospitalisations/year [-1.05, p < 1 x 10-5], and surgeries/year [-0.19, p = 0.065] were seen with algorithm-predicted remission. CONCLUSIONS: A machine learning algorithm was able to identify IBD patients on thiopurines with algorithm-predicted objective remission, a state associated with significant clinical benefits, including decreased steroid prescriptions, hospitalisations, and surgeries. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation (ECCO) 2017. This work is written by US Government employee and is in the public domain in the US
BACKGROUND AND AIMS: Big data analytics leverage patterns in data to harvest valuable information, but are rarely implemented in clinical care. Optimising thiopurine therapy for inflammatory bowel disease [IBD] has proved difficult. Current methods using 6-thioguanine nucleotide [6-TGN] metabolites have failed in randomized controlled trials [RCTs], and have not been used to predict objective remission [OR]. Our aims were to: 1) develop machine learning algorithms [MLA] using laboratory values and age to identify patients in objective remission on thiopurines; and 2) determine whether achieving algorithm-predicted objective remission resulted in fewer clinical events per year. METHODS: Objective remission was defined as the absence of objective evidence of intestinal inflammation. MLAs were developed to predict three outcomes: objective remission, non-adherence, and preferential shunting to 6-methylmercaptopurine [6-MMP]. The performance of the algorithms was evaluated using the area under the receiver operating characteristic curve [AuROC]. Clinical event rates of new steroid prescriptions, hospitalisations, and abdominal surgeries were measured. RESULTS: Retrospective review was performed on medical records of 1080 IBD patients on thiopurines. The AuROC for algorithm-predicted remission in the validation set was 0.79 vs 0.49 for 6-TGN. The mean number of clinical events per year in patients with sustained algorithm-predicted remission [APR] was 1.08 vs 3.95 in those that did not have sustained APR [p < 1 x 10-5]. Reductions in the individual endpoints of steroid prescriptions/year [-1.63, p < 1 x 10-5], hospitalisations/year [-1.05, p < 1 x 10-5], and surgeries/year [-0.19, p = 0.065] were seen with algorithm-predicted remission. CONCLUSIONS: A machine learning algorithm was able to identify IBD patients on thiopurines with algorithm-predicted objective remission, a state associated with significant clinical benefits, including decreased steroid prescriptions, hospitalisations, and surgeries. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation (ECCO) 2017. This work is written by US Government employee and is in the public domain in the US
Authors: Akbar K Waljee; Joel C Joyce; Sijian Wang; Aditi Saxena; Margaret Hart; Ji Zhu; Peter D R Higgins Journal: Clin Gastroenterol Hepatol Date: 2009-10-14 Impact factor: 11.382
Authors: Max Reinshagen; Ekkehard Schütz; Victor W Armstrong; Christoph Behrens; Christian von Tirpitz; Andreas Stallmach; Hans Herfarth; Jürgen Stein; Peter Bias; Guido Adler; Maria Shipkova; Wolfgang Kruis; Michael Oellerich; Nicolas von Ahsen Journal: Clin Chem Date: 2007-05-10 Impact factor: 8.327
Authors: T Dassopoulos; M C Dubinsky; J L Bentsen; C F Martin; J A Galanko; E G Seidman; R S Sandler; S B Hanauer Journal: Aliment Pharmacol Ther Date: 2013-11-17 Impact factor: 8.171
Authors: Remo Panaccione; Subrata Ghosh; Stephen Middleton; Juan R Márquez; Boyd B Scott; Laurence Flint; Hubert J F van Hoogstraten; Annie C Chen; Hanzhe Zheng; Silvio Danese; Paul Rutgeerts Journal: Gastroenterology Date: 2014-02 Impact factor: 22.682
Authors: Amit G Singal; Ashin Mukherjee; B Joseph Elmunzer; Peter D R Higgins; Anna S Lok; Ji Zhu; Jorge A Marrero; Akbar K Waljee Journal: Am J Gastroenterol Date: 2013-10-29 Impact factor: 10.864
Authors: Akbar K Waljee; Rachel Lipson; Wyndy L Wiitala; Yiwei Zhang; Boang Liu; Ji Zhu; Beth Wallace; Shail M Govani; Ryan W Stidham; Rodney Hayward; Peter D R Higgins Journal: Inflamm Bowel Dis Date: 2017-12-19 Impact factor: 5.325
Authors: Akbar K Waljee; Kay Sauder; Anand Patel; Sandeep Segar; Yiwei Zhang; Ji Zhu; Ryan W Stidham; Ulysses Balis; Peter D R Higgins Journal: J Crohns Colitis Date: 2018-01-05 Impact factor: 9.071
Authors: David Chen; Clifton Fulmer; Ilyssa O Gordon; Sana Syed; Ryan W Stidham; Niels Vande Casteele; Yi Qin; Katherine Falloon; Benjamin L Cohen; Robert Wyllie; Florian Rieder Journal: J Crohns Colitis Date: 2022-03-14 Impact factor: 10.020
Authors: Shirley Cohen-Mekelburg; Sameer Berry; Ryan W Stidham; Ji Zhu; Akbar K Waljee Journal: J Gastroenterol Hepatol Date: 2021-02 Impact factor: 4.029
Authors: John Gubatan; Steven Levitte; Akshar Patel; Tatiana Balabanis; Mike T Wei; Sidhartha R Sinha Journal: World J Gastroenterol Date: 2021-05-07 Impact factor: 5.742